Figure 5
From: Efficient Blockade of Akt signaling is a determinant factor to overcome resistance to Matuzumab
Targeting PI3K could overcome resistance to matuzumab. (A) Effects of combined treatment of matuzumab (100 μg/mL) with a PI3K inhibitor, LY294002 (10 μM), on the colony formation of A431, Caski and C33A cells by clonogenic assay (CA). (B) Representative pictures of colonies of A431, Caski and C33A cells after treatments with matuzumab (100 μg/mL) and/or LY294002 (10 μM) in CA and (C) WB analysis of total and phosphorylated Akt (Ser 473) on A431, Caski and C33A cells. (D) Effects of combined treatment of matuzumab and LY 294002 on the apoptosis of gynecological cancer cell lines analyzed by annexin V staining. (E) Cells were incubated alone or in the presence of 4 μg/mL of matuzumab for 4 h and exposed to peripheral blood mononuclear cells (PBMCs, effector cells) at effector/target ratio (E/T) of 20:1 for more 4 h and specific cytolysis (ADCC) was measured. Student's t test * P < 0.05, when compared to control cells.